



Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX RELEASE

Presentation to J.P. Morgan Healthcare Conference and Q4 Revenue Update

Melbourne (Australia) – 8 January 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises it is presenting at the 42nd Annual J.P. Morgan Healthcare Conference (8-11 January 2024) in San Francisco.

As part of the Company's presentation (lodged with this announcement), Telix has provided an update on unaudited revenue for Q4 2023, with the Company reporting \$148.1M (US\$97.1M¹) of total product revenue, primarily generated from sales of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the United States, an increase of 11% on the prior quarter (Q3 2023) total revenue of \$133.6M (US\$87.2M²). The total revenue (unaudited) for FY 2023 is \$502.5M (US\$333.0M³).

U.S. revenue was US\$95.1M, a record revenue quarter, with an increase of 12% on the prior quarter (US\$85.2M in Q3 2023) and 19% increase in dose volume.

Group CEO and Managing Director, Dr. Christian Behrenbruch stated, "We are delighted to be providing an update for investors at this leading global investment conference. In addition to showcasing the continued strong commercial performance of Illuccix, which is generating significant revenue, we will share an update of progress across the pipeline as we advance multiple late-stage therapeutic programs, prepare to bring two additional imaging agents to market and continue the vertical integration of supply and manufacturing."

The presentation will take place on Tuesday 9 January at 3:00pm PST (6:00pm EST / 10:00am AEDT 10 January).

Participants can register for the webcast at the following [link](#).

Telix expects to report its full year financial results for the year ended 31 December 2023 on Thursday 22 February 2024.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on [X](#) and [LinkedIn](#).

¹ Conversion to AUD\$ is at an average exchange rate realised during Q4 2023 of AUD\$1 = US\$0.656

² Conversion to AUD\$ is at an average exchange rate realised during Q3 2023 of AUD\$1 = US\$0.652

³ Conversion to AUD\$ is at an average exchange rate realised during the year of AUD\$1 = US\$0.663

Telix's lead imaging product, gallium-68 (⁶⁸Ga) gozetotide injection (also known as ⁶⁸Ga PSMA-11 and marketed under the brand name Illuccix[®]), has been approved by the U.S. Food and Drug Administration (FDA),⁴ by the Australian Therapeutic Goods Administration (TGA),⁵ and by Health Canada.⁶

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website.

©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).

⁴ Telix ASX disclosure 20 December 2021.

⁵ Telix ASX disclosure 2 November 2021.

⁶ Telix ASX disclosure 14 October 2022.